NeutralLOW severityHealthcare & Pharma7d ago

Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029

Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029 — $LQDA one-month chart
$LQDA daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Liquidia’s stock hit a 5.41% gain, closing near $58.20, just shy of its 52-week high. It now sits around the middle of its range, between $22.31 and $93.61, with steady coverage leaning slightly bullish. The Health Care sector shows calm today.

Written by Wook AI Nov 12, 1:57 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about LQDA. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · liquidiaEvent risk Low

Nothing reported about liquidia across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 78% a year
Now $56.73Week $50.52–$62.94 (±11.0%)Month $44.00–$69.46 (±22.4%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Drugmakers thrive on progress — late-stage trials are the real game, not quarterly earnings.
  • How the stock is trading: $LQDA -0.12% in the latest session.
  • Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.

Where the stock stands

Liquidia ($LQDA) slipped 0.12% to $56.30 in the latest session. Over the past month it is up 66.2%. That leaves it 40% below its 52-week high of $93.61 and 152% above its low of $22.31. It has been a volatile year: the high was 4.2 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Nov 10, 2026), $LQDA lost $236.3M over the quarter to Sep 30, 2026 on revenue of $225.3M (+31.2% QoQ). Operations brought in $279.9M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $248.9M. Total liabilities were $708.4M against $396.1M of cash on Sep 30, 2026. Liabilities of $708.4M exceeded assets of $682.9M on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $LQDA's own account and the first thing to read. Figures are as filed with the SEC; the $LQDA page has the full statements.

How much coverage it is getting

Wook has filed 3 stories on Liquidia in the last 30 days, 1 of them this week. That is a little busier than usual: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 3 neutral and 0 bearish. This one reads neutral too, in line with most of them. Seeking Alpha wrote 2 of the 3 (67%), so the count reflects one outlet's output more than broad attention.

The bigger picture

In healthcare, timing is everything — trial results, FDA rulings, and pricing shifts can turn a drugmaker's fate in an instant. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The $LQDA page has all the charts, filings, and models. One outlet dominates the story, so checking another is key to seeing if it's confirmed or just echoed. Wook AI can fetch live data and crunch the numbers — how far $LQDA is from its peak, or how this week's coverage stacks up.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 10, 2026. $LQDA has moved +11.49% ($50.50 to $56.30). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy